Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China
NCT05184231 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2023-03-17
Summary
The purpose of the protocol is to achieve an in-depth understanding of the current satisfaction status of somatostatin analogue (SSA) treatment for acromegaly through patient and physician surveys.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-02-13
- Primary Completion
- 2023-10-31
- Completion
- 2023-10-31
More Related Trials
-
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
NCT02354508 ·Status: COMPLETED ·Phase: PHASE3
-
Acromegaly Treatment Quality of Life Study
NCT01732406 ·Status: COMPLETED
-
Non Interventional Post Marketing Programme in Acromegaly
NCT00747500 ·Status: COMPLETED
-
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
NCT00088582 ·Status: COMPLETED ·Phase: PHASE2
-
Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues
NCT02427295 ·Status: UNKNOWN ·Phase: PHASE4
-
Prediction of Tumor Shrinkage in Acromegaly
NCT00616408 ·Status: COMPLETED
-
Somatuline Predictive Factors in Acromegaly and NET
NCT01840449 ·Status: COMPLETED
-
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
NCT00171730 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly
NCT04003519 ·Status: WITHDRAWN
-
A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
NCT01861717 ·Status: TERMINATED ·Phase: PHASE4
-
Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
NCT00994214 ·Status: TERMINATED ·Phase: PHASE2
-
Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone
NCT01029275 ·Status: COMPLETED ·Phase: NA
-
Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target
NCT01618513 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
NCT02493517 ·Status: COMPLETED ·Phase: PHASE3
-
Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery
NCT05149495 ·Status: UNKNOWN
-
Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects
NCT01723748 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
NCT00234572 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Non Interventional Study For Patients Treated With Somavert®
NCT00858143 ·Status: COMPLETED
-
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
NCT01673646 ·Status: COMPLETED ·Phase: PHASE2
-
Predictive Factors Study
NCT02020499 ·Status: TERMINATED
-
Surgical Versus Medical Treatment of Acromegaly
NCT01000090 ·Status: COMPLETED
-
Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.
NCT01283542 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
NCT00225979 ·Status: COMPLETED ·Phase: PHASE3
-
Acromegaly: Patient And Physician Perspectives
NCT03613623 ·Status: COMPLETED
-
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
NCT01995734 ·Status: APPROVED_FOR_MARKETING